Journal of Cancer Research and Therapeutics

CASE REPORT
Year
: 2020  |  Volume : 16  |  Issue : 5  |  Page : 1191--1195

Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation


Zhigang Wei1, Xia Yang2, Xin Ye1 
1 Department of Oncology, The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong Province, China
2 Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China

Correspondence Address:
Xin Ye
Department of Oncology,The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute. No. 16766, Jingshi Road, Jinan, Shandong Province, 250014
China

Camrelizumab is a programmed death receptor-1 inhibitor originally developed in China for the treatment of refractory lymphoma. It has also been effective in non-small-cell lung cancer patients. However, the rechallenge of camrelizumab was not reported previously. We report the rechallenge of camrelizumab therapy in two patients previously treated with microwave ablation (MWA) and camrelizumab. Although objective responses were achieved, camrelizumab therapy was discontinued because of the development of immune-related pneumonia (IRP). Treatment with camrelizumab was reinitiated after the patients recovered from IRP. The reoccurrence of more severe IRP necessitated additional corticosteroid therapy. The rechallenge of camrelizumab in patients treated with MWA plus camrelizumab regimen and who developed IRP should be cautious.


How to cite this article:
Wei Z, Yang X, Ye X. Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation.J Can Res Ther 2020;16:1191-1195


How to cite this URL:
Wei Z, Yang X, Ye X. Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation. J Can Res Ther [serial online] 2020 [cited 2020 Nov 27 ];16:1191-1195
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2020;volume=16;issue=5;spage=1191;epage=1195;aulast=Wei;type=0